<DOC>
	<DOCNO>NCT02993822</DOCNO>
	<brief_summary>The purpose study determine effectiveness three dos orvepitant , take day , treatment chronic refractory cough .</brief_summary>
	<brief_title>A Dose-ranging Study Orvepitant Patients With Chronic Refractory Cough</brief_title>
	<detailed_description>A multi-center , double-blind , randomize , parallel group , placebo-controlled dose range study subject chronic refractory cough ( CRC ) . Doses orvepitant ( 10 mg/day , 20 mg/day 30 mg/day ) placebo investigate four parallel group . Each group compromise approximately 61 subject , randomize 1:1:1:1 ( approximately 244 subject total ) . Assuming drop-out rate 10 % total approximately 220 subject expect complete study . All subject enter three-week screening period determine eligibility . Eligible subject randomize Baseline/Day 1 visit enter 12-week double-blind dosing period . During period four visit Weeks 2 , 4 , 8 12 . There final safety follow-up visit Week 14 .</detailed_description>
	<mesh_term>Cough</mesh_term>
	<criteria>1 . Male female subject ≥18 year age . 2 . Able understand comply requirement study sign Informed Consent form . 3 . Diagnosis CRC unexplained cough least 1 year ( see ACCP/BTS guideline attach ) . 4 . A awake average cough frequency ≥10 coughs/ hour , assess use ACM screen period ( note , ACM wear 24hour period average waking cough frequency determine ) . 5 . Females must nonpregnant nonlactating intention pregnancy study treatment . 6 . Women childbearing potential ( WOCP ) ( i.e . surgically sterilised postmenopausal* ) must negative blood serum pregnancy test perform Screening visit agree use two method birth control , one must barrier method ( note : double barrier method consider acceptable ) duration participation study . Postmenopausal define &gt; 1 year since last menstrual period woman &gt; 55 year age &gt; 1 year since last menstrual period FSH level menopausal range woman &lt; 55years age . Acceptable method birth control : Surgical sterilization subject 's male partner ( vasectomy document azoospermia ) sole partner subject . Established hormonal contraception ( implantable , patch , oral intramuscular [ IM ] ) administer least one month prior investigational product administration continue least 4 week last dose investigational product . An intrauterine device ( IUD ) intrauterine system ( IUS ) failure rate le 1 % per year insert qualified physician least one month prior investigational product administration remain place least 4 week last dose investigational product . Barrier method male condom cap , diaphragm sponge spermicide . 7 . Male subject partner childbearing potential must use two method acceptable birth control , one must barrier method , make donation sperm screen 90 day last dose investigational product . 1 . Subjects respiratory tract infection ( &lt; 4 week prior study start ) 2 . Females breast feed pregnant 3 . Current smoker exsmokers &lt; 6 month ' abstinence cumulative history &gt; 10 pack year 4 . Treatment Angiotensin Converting Enzyme ( ACE ) inhibitor within 3 month screen 5 . A history drug alcohol abuse within 12 month screen 6 . FEV1 &lt; 80 % predict , measure screen use spirometry 7 . History cystic fibrosis , idiopathic pulmonary fibrosis , clinically significant bronchiectasis , moderate severe asthma , chronic obstructive pulmonary disease ( COPD ) 8 . Uncontrolled hypertension ( &gt; 160/90 mmHg despite adequate medical therapy ) screen baseline 9 . Recent myocardial infarction ( within 1 year ) , history congestive cardiac failure 10 . Any clinically significant abnormality 12lead ECG screen baseline 11 . Subjects prior renal transplant , current renal dialysis , history renal tubular acidosis . 12 . Any clinically significant neurological disorder 13 . Any clinically significant unstable medical psychiatric condition would interfere subject 's ability participate study 14 . Subjects prior medical history increase risk seizure ( except febrile seizure infancy ) , history recent head trauma ( within last 6 month ) result loss consciousness concussion 15 . Any malignancy past 5 year unless noninvasive remission ( diseasefree &gt; 5 year ) write approval obtain Sponsor , exception skin cancer include malignant melanoma 16 . Any clinically significant abnormal laboratory test result ( ) , include : Serum creatinine laboratory value great 1.5 x upper limit normal estimate creatinine clearance &lt; 60 mL/ min ( use CockcroftGault formula ) Total bilirubin great &gt; 1.5 time upper limit normal ( exception Gilbert 's Syndrome ) Alanine transaminase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal 17 . Inability comply use prohibit allowed medication describe : The use opioids , gabapentin , pregabalin , baclofen , tricyclic antidepressant ( e.g . amitriptyline ) allow throughout study . Subjects must discontinue drug least 1 month prior screen Concomitant respiratory medication allow , subject must stable medication take duration study Other medication use manage cough describe permit provided dose stable least 3 month remain stable throughout participation study Use digoxin allow screen 1 week last dose study medication Use know CYP3A4 substrates narrow therapeutic range allow screen 1 week last dose study medication ( include limit alfentanil , cyclosporine , dihydroergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus ) Use strong moderate inhibitor CYP3A4 allow screen 1 week last dose study medication ( include limit clarithromycin , erythromycin , grapefruit juice , indinavir , lopinavir , ritonavir , saquinavir , atazanavir , itraconazole , ketoconazole , voriconazole , fluconazole , posaconazole , cimetidine , cyclosporine , diltiazem , fluvoxamine , imatinib , verapamil ) Use inducer CYP3A4 allow screen 1 week last dose study medication ( include limit rifampicin , carbamazepine , efavirenz , bosentan , modafinil , St. John 's Wort ) Use know Pglycoprotein inhibitor allow screen 1 week last dose study medication ( include limit amiodarone , azithromycin , carvedilol , clarithromycin , conivaptan , cyclosporine , diltiazem , dronedarone , erythromycin , felodipine , itraconazole , ketoconazole , lopinavir ritonavir , quinidine , ranolazine , verapamil ) 18 . Participation clinical research study evaluate another investigational drug therapy within 30 day within 5 halflives ( whichever longer ) investigational drug prior screen . If subject observational clinical study washout require 19 . Subjects receive aprepitant ( Emend® ) fosaprepitant ( Ivemend® ) , NK1 antagonists license antiemetic &lt; 4 week Screening visit 20 . Subjects previously receive orvepitant time 21 . Known allergy excipients use investigational product ( orvepitant placebo tablet ) 22 . Subjects , opinion Investigator , participate study reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>